Does histopathological examination of breast reduction specimens affect patient management and clinical follow up?

Journal of Clinical Pathology

Volumn 57, Issue 3, 2004, Pages 286-289

  Cook, I S ^a,b   Fuller, C E ^b  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b SALISBURY DISTRICT HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST DISEASE; BREAST REDUCTION; BREAST SURGERY; CANCER DIAGNOSIS; CANCER INVASION; CARCINOMA IN SITU; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICAL RECORD; MICROSCOPE; PATIENT CARE; PRIORITY JOURNAL; SURGICAL PATIENT;

ADOLESCENT; ADULT; AGED; BREAST; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; HYPERPLASIA; MAMMAPLASTY; MIDDLE AGED; NEOPLASM INVASIVENESS;

EID: 1542616440     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2003.012427     Document Type: Article

References (17)

1. Royal College of Pathologists. Histopathology of limited or no clinical value. RCPath publication 2002. London: Royal College of Pathologists.
2. Jansen DA, Murphy M, Kind GM, et al. Breast cancer in reduction mammoplasty: case reports and a survey of plastic surgeons. Plast Reconstr Surg 1998;101:361-4.
3. Bondeson L, Linell F, Ringberg A. Breast reductions: what to do with all the tissue specimens? Histopathology 1985;9:281-5.
4. Snyderman RK, Lizardo JG. Statistical study of malignancies found before, during, or after routine breast plastic operations. Plast Reconstr Surg 1960;25:253-6.
5. Lakhani SR. The transition from hyperplasia to invasive carcinoma of the breast. J Pathol 1999;187:272-8.
6. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146-51.
7. London SJ, Connolly JL, Schnitt SJ, et al. A prospective study of benign breast disease and the risk of breast cancer. JAMA 1992;267:941-4.
8. Dupont WD, Pari FF, Hartmann WH, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 1993;71:1258-65.
9. Page DL, Jensen RA. Evaluation and management of high risk and premalignant lesions of the breast. World J Surg 1994;18:32-8.
10. Ciatto S, Andreoli C, Cirillo A, et al. The risk of breast cancer subsequent to histo ogic diagnosis of benign intraductal papilloma. Follow-up study of 339 cases. Tumori 1991;77:41-3.
11. Page DL, Dupont WD. Premalignant conditions and markers of devoted risk in the breast and their management. Surg Clin North Am 1990;70:831-51.
12. Lakhani SR, Collins N, Stratton MR, et al. Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J Clin Pathol 1995;48:611-15.
13. Lishman SC, Lakhani SR. Atypical lobular hyperplasia and lobular carcinoma-in-situ: surgical and molecular pathology. Histopathology 1999;35:195-200.
14. Welch HG, Black WC. Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breash how much more breast cancer can we find? Ann Intern Med 1997;127:1023-8.
15. Simmons RM, Osborne MP. The evaluation of high-risk and pre-invasive breast lesions and the decision process for follow-up and surgical intervention. Surg Oncol 1999;8:55-65.
16. Jacobs TW, Connolly JL, Schnitt SJ. Nonmalignant lesions in breast core needle biopsies: to excise or not to excise? Am J Surg Pathol 2002;26:1095-110.
17. NHS Breast Screening Programme. Annual Review 2001. NHSBSP Publications. Sheffield: NHSBSP Publication.